Specific results through streamlined testing

Mayo Clinic Laboratories’ updated approach to fluorescence in situ hybridization (FISH) testing was designed to simplify the ordering process and provide appropriate testing to meet individual patient needs. Testing options for adult and pediatric patients are now available by disease state, including only the most relevant genetic probes, while specified panels continue to provide flexibility to select probe offerings.

Our approach provides:

• Panels tailored to disease state and demographics to meet individual patient needs, as well as specific testing options for diagnosis vs. follow-up monitoring
• Thoughtfully crafted panels to promote utilization management and avoid over- or under-ordering of applicable tests
• Confidence that patients receive the right test the first time
• Simplified ordering processes with increased understanding of testing performed
• Alignment with testing recommendations by the National Comprehensive Cancer Network (NCCN) and the CLL-International Prognostic Index (CLL-IPI)

Affected testing subspecialties

---

Acute myeloid leukemia

---

B-cell lymphoma

---

B-cell and T-cell acute lymphoblastic leukemia

---

Children’s Oncology Group

---

Chronic lymphocytic leukemia

---

Eosinophilia

---

Myelodysplastic syndrome

---

T-cell lymphoma

---

Plasma cell neoplasms

---

How to order